On April 29th, local time in the UK, AstraZeneca disclosed during its latest earnings conference that the company might incur an additional fine of $8 million in China due to unpaid taxes on the imported breast cancer drug Enhertu. Previously, AstraZeneca had already faced a maximum penalty of $4.5 million for similar tax evasion on two other cancer drugs, Imfinzi and Imjudo.